Our Science – Bottaro Website
Donald P. Bottaro, Ph.D.
Research in Urologic Oncology Branch is aimed at identifying the genetic and biochemical defects that contribute to genitourinary malignancies, and to translating these discoveries into safe and effective treatment strategies. The discovery of germline mutations in the HGF receptor, Met, that predispose affected individuals to papillary renal cell carcinoma (HPRC) type 1, significantly strengthened mounting evidence of the oncogenic potential of this signaling pathway. Normally, HGF stimulates proliferation, motility and morphogenesis in a wide spectrum of cell types, contributing to embryonic development and to tissue repair in adulthood. Abnormal activation of the HGF pathway has been found in many human cancers, including carcinomas of the bladder, breast, colon, liver, lung, kidney and thyroid, sarcomas of bone and muscle, leukemia, lymphoma, glioblastoma and melanoma. In many of these cancers, HGF/Met signaling drives cell invasiveness and tumor metastasis, advancing disease beyond current effective therapies. Understanding the molecular basis of oncogenic signaling and developing strategies for its selective disruption in cancer are our highest priorities.
This page was last updated on 7/29/2014.